Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.

Sci Rep · 2026 · PMC13090346 · PMID 41998023

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

marginally non-significantp ≤ 0.056so close (0.05 < p ≤ 0.1)

For the 10–16 kHz DPOAE, the comparison with the pre-treatment group showed a marginally non-significant difference after the first cisplatin treatment ( p ≤ 0.056), whereas a significant reduction was observed after the second treatment ( p ≤ 0.02; Bonferroni-corrected).

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.